| 2026-08-13 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-12 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-12 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-10 | Press release | Omeros Corporation to Announce Second Quarter Financial Results on · 2026 |
| 2026-08-03 | Press release | CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® · FY 2027 |
| 2026-07-20 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-06 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-26 | Press release | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA |
| 2026-06-25 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-18 | Press release | Omeros Announces Webcast Details for Annual Meeting of Shareholders |
| 2026-06-18 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-15 | Press release | Download , Omeros Announces Webcast Details for Annual Meeting of Shareholders |
| 2026-05-15 | Transcript | Q1 FY26 earnings call transcript |
| 2026-05-13 | Press release | Omeros Corporation Reports First Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET |
| 2026-05-13 | Press release | Omeros Corporation to Announce First Quarter Financial Results on · 2026 |
| 2026-05-13 | Press release | Press Release of Q1 2026 |
| 2026-05-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-13 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| Transcript | Q1 FY26 earnings call transcript |
| 2026-05-11 | Press release | Download , Omeros Corporation to Announce First Quarter Financial Results on , (opens in new w · 2026 |
| 2026-04-30 | Proxy | Proxy Statement of 2025 Annual Report |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-04-16 | Press release | CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) |
| 2026-03-31 | Press release | Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results |
| 2026-03-31 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-31 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-26 | Press release | Download , Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on , March 2 |
| 2026-03-26 | Press release | Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on |
| 2026-03-21 | Press release | Download , Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment |
| 2026-03-21 | Press release | Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment |
| 2026-02-17 | Press release | Download , Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program, (opens in new wind |
| 2026-02-17 | Press release | Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program |
| 2026-01-27 | Press release | Download , Omeros Announces First Commercial Sales of YARTEMLEA® |
| 2026-01-27 | Press release | Omeros Announces First Commercial Sales of YARTEMLEA® |
| Transcript | Earnings call transcript |
| 2026-01-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-29 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-26 | Press release | Omeros Announces New Date for YARTEMLEA® Approval Conference Call |
| 2025-12-24 | Press release | FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA |